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Purpose: Screening of mutations in the fibrillin-1 (FBN1) gene in a Chinese family with autosomal dominant Marfan
syndrome (MFS).
Methods: It has been reported that FBN1 mutations account for approximately 90% of Autosomal Dominant MFS.
FBN1 mutations were analyzed in a Chinese family of 36 members including 13 MFS patients. The genomic DNAs from
blood leukocytes of the patients and their relatives were isolated and the entire coding region of FBN1 was amplified by
PCR. The sequence of FBN1 was dertermined with an ABI 3100 Genetic Analyzer.
Results: A previously unreported the missense mutation G214S (caused by a 640 A→G heterozygous change) in FBN1
was identified in the Chinese family. The mutation was associated with the disease phenotype in patients, but not detected
in their relatives or in the 100 normal controls.
Conclusions: This is the first report of molecular characterization of FBN1 in the MFS family of Chinese origin. Our
results expand the spectrum of FBN1 mutations causing MFS and further confirm the role of FBN1 in the pathogenesis
of MFS. Direct sequencing of the mutation in FBN1 may be used for diagnosis of MFS.
Marfan  syndrome  (MFS)  is  an  inherited,  autosomal
dominant,systemic  disorder  of  connective  tissue.  The
estimated  prevalence  of  MFS  is  one  in  10,000  to  20,000
individuals.  It  is  well  known  that  three  major  systems:
skeletal,  ocular,  and  cardiovascular  are  affected  by  the
disease. The clinical criteria for MFS include a combination
of skeletal manifestations, ectopia lentis, dural ectasia, and
dilatation or dissection of the ascending aorta.
The main pathogenesis of MFS is currently thought to be
driven by mechanisms due to haploinsufficiency of wild-type
fibrillin-1 [1]. Fibrillins are ubiquitous extracellular matrix
molecules that assemble into microfibrils [2-4] and target
growth factors to the extracellular matrix [5-7]. Fibrillin-1
mutations disrupt microfibril formation, thereby resulting in
fibrillin protein abnormalities, and subsequently weakening
the connective tissue. More than 1000 mutations have been
identified  in  the  gene  for  fibrillin-1  (FBN1)  [8].  Most
mutations are unique for a certain MFS family, and only
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approximately 10% of mutations are recurrent in different
families [9].
FBN1 is a 230-kb gene with 65 exons that encodes the
structural protein fibrillin-1, located at chromosome 15q-21.1.
In  this  study,  we  analyzed  a  four-generation,  non-
consanguineous Chinese family, which has been diagnosed as
MFS, and identified a mutation in the 7th exon of FBN1 (c.
640 A→G) resulting in the substitution of glycine by serine
at codon 214 (p. G214S). Our data of FBN1 mutations causing
MFS further confirm the role of FBN1 in the pathogenesis of
MFS.  Obviously  this  is  the  first  report  of  molecular
characterization in FBN1 in the Chinese MFS family.
METHODS
Clinical data and 5 ml of blood samples were collected from
a Chinese Zhang family with MFS. The patient underwent
complete  physical  and  ophthalmic  examinations.  The
Institutional  Review  Board  approved  the  project  and
investigators followed the principles of the Declaration of
Helskinki. Informed consent was obtained from each person.
To identify constitutional mutations, blood specimens (8
ml) were collected in EDTA, and genomic DNA was extracted
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81from peripheral blood cells according to a standard protocol
(Roche Diagnostics Corporation, Indianapolis, IN). Briefly,
all  the  exons  and  exon-intron  boundaries  of  FBN1  were
amplified  by  using  the  standard  PCR  buffer  system  with
primers  listed  in  Appendix  1.  PCR  reactions  were  each
performed in a 10 µl volume, containing 1.5 mM MgCl2, 0.4
mM  of  each  primer,  200  µM  dNTPs,  1  U  Taq  DNA
polymerase, and 10-20 ng template DNA. Amplification was
performed with an initial denaturation for 3 min at 95 °C,
followed by 30 cycles of denaturation at 95 °C for 1 min,
annealing at 55 °C for 1 min, extension at 72 °C for 1 min,
and a final extension at 72 °C for 3 min.
PCR products were purified by using a PCR product
purification kit (QIAquick; Qiagen, Valencia, CA). Purified
PCR products were sequenced using the BigDye Terminator
Cycle Sequencing v3.1 kit (Applied Biosystems, Foster City,
CA). Briefly, about 10 ng of template DNA is added to each
reaction and using a temperature program which included 25
cycles of denaturation at 97 °C for 30 s, annealing at 50 °C
for 15 s, and extension at 60 °C for 4 min. All samples were
analyzed in an ABI Prism 310 Genetic Analyzer (Applied
Biosystems).  The  FBN1  CDNA  reference  sequence  with
GenBank  accession  number  NC_000015.9  was  used
(National  Center  for  Biotechnical  Information  [NCBI],
Bethesda, Md).
RESULTS
The patients including 8 males and 5 females were from a
family in Guangdong Province, China (Figure 1). All of these
patients  in  the  family  manifested  various  reduced  visual
acuities with a bilateral lens dislocation and high myopia.
Aortic root dilatation was present in 2 of the 13 patients. One
patient had an aortic aneurysm together with either aortic
valve stenosis or aortic valve insufficiency. The other patient
had  a  cloverleaf  appearance  in  the  cross-section,  but  the
diameter of his aortic root was apparently normal. All patients
had facial and skeletal features of MFS including joint laxity,
dolichostenomelia, pectus excavatum or pectus carinatum,
and scoliosis (Table 1). The cause of death for two patients
was cardiovascular malformations.
Sequencing  of  the  65  coding  exons  of  FBN1  in  the
patients revealed a mutation (c. 640 A→G; Figure 2) which
resulted in substitution of glycine by serine (G214S) in exon
7. The mutation was linked to the disease phenotype in all
patients, but not found in other unaffected relatives or in the
100 normal controls.
DISCUSSION
MFS is diagnosed using the Ghent criteria, a group of clinical
findings  that  are  specific  for  MFS.  The  Ghent  criteria  is
through  a  comprehensive  assessment  largely  based  on  a
combination of major and minor clinical manifestations in the
various organ systems and the family history [10]. Although
the clinical manifestations of the cardiovascular, ocular, and
skeletal systems are important criteria for diagnosis of the
disease,  a  family  genetic  history  can  also  provide  useful
information for determining etiology and designing treatment
strategy.  For  example,  an  individual  with  these  clinical
features  such  as  tall,  thin  body  habitus,  long  limbs,
arachnodactyly, pectus deformities, and sometimes scoliosis
with  family  history  may  be  suggestive  of  a  diagnosis  of
Marfan’s syndrome [11].
Cardiovascular  malformations  are  the  most  life-
threatening presentations of MFS. Affected patients are at risk
for  aortic  dissection  and/or  severe  ocular  and  orthopedic
disorders.  Although  we  have  observed  the  following
Figure 1. The pedigree of the family is shown. Squares and circles indicate males and females, respectively, and the darkened symbols represent
the affected members. The patient above the arrow is the proband.
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82cardiovascular manifestations of MFS: mitral valve prolapse,
calcification of the mitral valve annulus and dilatation or
dissection  of  the  descending  aorta,  the  prevalence  of
cardiovascular manifestations is not very high in this family.
The clinical manifestations of the MFS patients in the
family become more evident with age. The most common
symptom among them is myopia and 100% of the patients
have ectopia lentis. Besides, there was one patient with retinal
detachment and two patients underwent IOL surgery.
The pathogenesis of the Marfan’s syndrome has not been
fully  elucidated.  FBN1  mutations  are  believed  to  exert  a
dominant negative effect [12]. In this study we identified a
novel  FBN1  mutation  in  patients  by  genotype-phenotype
analysis, which perfectly met the Ghent criteria (p=0.005).
The mutation was also detected in those who had ectopia lentis
(EL; p<0.0001) [13].
In  rare  cases,  MFS  is  caused  by  a  mutation  in  the
transforming growth factor beta (TGF-β) receptor 1 or 2 genes
[14-16].
The coding sequence of FBN1 is spread over 65 coding
exons. FBN1 is comprised mainly of repeated modules such
as  epidermal-growth-factor  like  (EGF)  domains  and
transforming  growth  factor  β1  binding  protein-like  (TB)
Figure 2. A novel FBN1 missense mutation in extron 7. The partial
nucleotide sequence of FBN1 in is shown. A: The corresponding
normal sequence in an unaffected family member. B: A heterozygous
change A→G (indicated by the arrow) was identified in an affected
family member.
TABLE 1. CLINICAL EVALUATION OF AFFECTED FAMILY MEMBERS.
* Operated for ectopia lentis.
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Patient ID II:3 II:9 II:4 II:9 II:11 II:14 IV:1 IV:3 IV:7
Age 69 59 41 37 32 26 12 9 5
Sex F F F M F M M M M
Ocular system
(1) Ectopia lentis + + + OEL* + + + + +
(2) Myopia + + + OEL* + + + + +
(3) Strabismus + -  - - - - + - -
(4) Glaucoma - - - + - - - - -
(5) Retinal detachment - - - - - - + - -
Cardiovascular system
(1) Aortic root dimension (mm) 31.6 29 27.5 39.2 26 25.1 24.9 24 20.3
(2) Mitral valve prolapse - - - + - - - - -
(3) aortic aneurysm + - - - - - - - -
Skeletal system
(1) Height (H;cm) 168 170 172 192 174 198 171 168 145
(2) Arm span (AS;cm) 173 175 178 201 180 208 179 177 149
(3) AS/H 1.03 1.03 1.03 1.05 1.03 1.05 1.04 1.05 1.02
(4) Scoliosis - - - + - - - - -
(5) Arachnodactyly + + + + + + + + -
(6) Joint hypermobility + + - - - - - - -
(7) pectus excavatum + + - - - - - - -
(8) Pectus carinatum - - - - - - + + -
Other manifestations
(1) Hyperextensible skin + + - - - - - - -
(2) Striae + + - - - - - - -
(3) Hernia - - - - - - - - +domains. There are a total of 47 EGF domains on the protein.
Among them, 43 of which are of the calcium-binding (cb) type
(cb-EGF). There are also 7 TB domains distributed throughout
FBN1, separated by variable numbers of the tandem repeated
EGF domains [17-19]. Most mutations of FBN1 occur in the
EGF domains [20].
FBN1 mutations disrupt microfibril formation, thereby
resulting in fibrillin protein abnormalities, and subsequently
weakening  the  connective  tissue  [21].  Over  601  distinct
mutations  have  been  documented  in  the  Marfan  mutation
database  [22].  Two-thirds  of  the  mutations  are  missense
mutations, and the majority of these are cysteine substitutions.
Nonsense mutations account for about 10% of all reported
mutations.  Small  insertions,  deletions,  or  duplications
represent about 13% among these mutations. Another 13% of
the  reported  mutations  are  caused  by  various  classes  of
splicing errors [23].
Interestingly, mutations frequently occur in exons 2, 15,
22, 27, 46, 55, and 62 but much less in exons 7, 41, and 65
[24] although the cause remains to be elucidated. According
to Universal Marfan Database – FBN1 (UMD-FBN), only 2
different mutations in exon7 have been reported [25,26].
The new mutation we identified was a missense mutation
in exon 7 (640 A→G heterozygous change) of FBN1 in the
Chinese family. This mutation was found in all patients, but
not  in  unaffected  family  members  and  the  100  unrelated
controls, suggesting that the new mutation may be responsible
for the pathogenesis of MFS in this family.
Sequences for TB domains found in fibrillin show a high
level  of  amino  acid  conservation.  The  TB  domain  is
characterized  by  eight  cysteines  predicted  to  form  four
intraomolecular  disulphide  bonds.  There  are  totally  11
reported mutations in the TB domains of human FBN1 which
are associated with MFS. Structural analysis implicates that
those mutations involving cysteines (C661R, C711Y, C996R,
and C1589F) are likely to cause domain misfolding, since one
of the four disulfide bonds may be disrupted. Three mutations
related  to  either  a  frameshift  (N1713  and  E2105)  or  the
formation  of  a  premature  stop  codon  (Y2113X)  cause
disruption  of  the  primary  sequence  of  this  protein.  Point
mutations  in  the  TB  domains,  including  A705T,  V984I,
G1013R, and K1023N have also been reported [27]. Here we
report that the new mutation we identified in the TB1 domain
may interfere with microfibrillar assembly via producing an
unstable mutant protein cleavage products.
Conclusion—We  have  identified  a  single  missense
mutation in FBN1 (c.640 A→G). in a Chinese family with
Marfan syndrome. Our results expand the spectrum of FBN1
mutations  causing  MFS,  and  further  confirm  the  role  of
FBN1 in the pathogenesis of MFS. Direct sequencing of the
FBN1 mutation could be used for diagnosis of MFS.
ACKNOWLEDGMENTS
We are grateful to the patients and their family members for
their cooperation in this study. This study was supported by
the National Natural Science Foundation (No. 30950007) and
Beijing Natural Science Foundation (No. 7102160). The study
was  approved  by  the  Ethics  Committee  of  the  Peking
University Third Hospital and conformed to the Declaration
of Helsinki.
REFERENCES
1. Haneline  M,  Lewkovich  GN.  A  narrative  review  of
pathophysiological  mechanisms  associated  with  cervical
artery  dissection.  J  Can  Chiropr  Assoc  2007;  51:146-57.
[PMID: 17885677]
2. Sakai  LY,  Keene  DR,  Engvall  E.  Fibrillin,  a  new  350-kD
glycoprotein, is a component of extracellular microfibrils. J
Cell Biol 1986; 103:2499-509. [PMID: 3536967]
3. Zhang  H,  Apfelroth  SD,  Hu  W,  Davis  EC,  Sanguineti  C,
Bonadio J, Mecham RP, Ramirez F. Structure and expression
of fibrillin-2, a novel microfibrillar component preferentially
located in elastic matrices. J Cell Biol 1994; 124:855-63.
[PMID: 8120105]
4. Charbonneau NL, Dzamba BJ, Ono RN, Keene DR, Corson
GM, Reinhardt DP, Sakai LY. Fibrillins can co-assemble in
fibrils, but fibrillin fibril composition displays cell-specific
differences.  J  Biol  Chem  2003;  278:2740-9.  [PMID:
12429739]
5. Isogai Z, Ono RN, Ushiro S, Keene DR, Chen Y, Mazzieri R,
Charbonneau NL, Reinhardt DP, Rifkin DB, Sakai LY. Latent
transforming growth factor beta-binding protein 1 interacts
with fibrillin and is a microfibril-associated protein. J Biol
Chem 2003; 278:2750-7. [PMID: 12429738]
6. Gregory KE, Ono RN, Charbonneau NL, Kuo CL, Keene DR,
Bächinger HP, Sakai LY. The prodomain of BMP-7 targets
the BMP-7 complex to the extracellular matrix. J Biol Chem
2005; 280:27970-80. [PMID: 15929982]
7. Sengle G, Charbonneau NL, Ono RN, Sasaki T, Alvarez J,
Keene  DR,  Bächinger  HP,  Sakai  LY.  Targeting  of  bone
morphogenetic protein growth factor complexes to fibrillin. J
Biol Chem 2008; 283:13874-88. [PMID: 18339631]
8. Faivre L, Collod-Beroud G, Loeys BL, Child A, Binquet C,
Gautier  E,  Callewaert  B,  Arbustini  E,  Mayer  K,  Arslan-
Kirchner M, Kiotsekoglou A, Comeglio P, Marziliano N,
Dietz HC, Halliday D, Beroud C, Bonithon-Kopp C, Claustres
M, Muti C, Plauchu H, Robinson PN, Adès LC, Biggin A,
Benetts B, Brett M, Holman KJ, De Backer J, Coucke P,
Francke U, De Paepe A, Jondeau G, Boileau C. Effect of
mutation  type  and  location  on  clinical  outcome  in  1,013
probands with Marfan syndrome or related phenotypes and
FBN1 mutations: an international study. Am J Hum Genet
2007; 81:454-66. [PMID: 17701892]
9. Collod-Béroud G, Le Bourdelles S, Ades L, Ala-Kokko L,
Booms P, Boxer M, Child A, Comeglio P, De Paepe A,
Hyland  JC,  Holman  K,  Kaitila  I,  Loeys  B,  Matyas  G,
Nuytinck  L,  Peltonen  L,  Rantamaki  T,  Robinson  P,
Steinmann B, Junien C, Béroud C, Boileau C. Update of the
UMD-FBN1  mutation  database  and  creation  of  an  FBN1
polymorphism  database.  Hum  Mutat  2003;  22:199-208.
[PMID: 12938084]
10. Gelb  BD.  Marfan's  syndrome  and  related  disorders–more
tightly  connected  than  we  thought.  N  Engl  J  Med  2006;
355:841-4. [PMID: 16929000]
Molecular Vision 2012; 18:81-86 <http://www.molvis.org/molvis/v18/a10> © 2012 Molecular Vision
8411. Dean  JC.  Marfan  syndrome:  clinical  diagnosis  and
management. Eur J Hum Genet 2007; 15:724-33. [PMID:
17487218]
12. Erentug V, Polat A, Bozbuga NU, Polat E, Erdogan HB, Kirali
K, Guler M, Akinci E, Yakut C. Cardiovascular reoperations
in Marfan syndrome. J Card Surg 2006; 21:455-7. [PMID:
16948755]
13. Robinson PN, Godfrey M. The molecular genetics of Marfan
syndrome  and  related  microfibrillopathies.  J  Med  Genet
2000; 37:9-25. [PMID: 10633129]
14. Mizuguchi  T,  Collod-Beroud  G,  Akiyama  T,  Abifadel  M,
Harada N, Morisaki T, Allard D, Varret M, Claustres M,
Morisaki H, Ihara M, Kinoshita A, Yoshiura K, Junien C,
Kajii  T,  Jondeau  G,  Ohta  T,  Kishino  T,  Furukawa  Y,
Nakamura  Y,  Niikawa  N,  Boileau  C,  Matsumoto  N.
Heterozygous TGFBR2 mutations in Marfan syndrome. Nat
Genet 2004; 36:855-60. [PMID: 15235604]
15. Singh  KK,  Rommel  K,  Mishra  A,  Karck  M,  Haverich  A,
Schmidtke J, Arslan-Kirchner M. TGFBR1 and TGFBR2
mutations in patients with features of Marfan syndrome and
Loeys Dietz syndrome. Hum Mutat 2006; 27:770-7. [PMID:
16799921]
16. Sakai H, Visser R, Ikegawa S, Ito E, Numabe H, Watanabe Y,
Mikami H, Kondoh T, Kitoh H, Sugiyama R, Okamoto N,
Ogata T, Fodde R, Mizuno S, Takamura K, Egashira M,
Sasaki N, Watanabe S, Nishimaki S, Takada F, Nagai T,
Okada Y, Aoka Y, Yasuda K, Iwasa M, Kogaki S, Harada N,
Mizuguchi T, Matsumoto N. Comprehensive genetic analysis
of relevant four genes in 49 patients with Marfan syndrome
or Marfan-related phenotypes. Am J Med Genet A 2006;
140:1719-25. [PMID: 16835936]
17. Handford  PA.  Fibrillin-1,  a  calcium  binding  protein  of
extracellular  matrix.  Biochim  Biophys  Acta  2000;
1498:84-90. [PMID: 11108952]
18. Corson GM, Chalberg SC, Dietz HC, Charbonneau NL, Sakai
LY. Fibrillin binds calcium and is coded by cDNAs that reveal
a multidomain structure and alternatively spliced exons at the
5′ end. Genomics 1993; 17:476-84. [PMID: 7691719]
19. Pereira  L,  D'Alessio  M,  Ramirez  F,  Lynch  JR,  Sykes  B,
Pangilinan  T,  Bonadio  J.  Genomic  organization  of  the
sequence coding for fibrillin, the defective gene product in
Marfan syndrome. Hum Mol Genet 1993; 2:961-8. [PMID:
8364578]
20. Dietz HC, Saraiva JM, Pyeritz RE, Cutting GR, Francomano
CA. Clustering of fibrillin (FBN1) missense mutations in
Marfan syndrome patients at cysteine residues in EGF-like
domains. Hum Mutat 1992; 1:366-74. [PMID: 1301946]
21. Cañadas V, Vilacosta I, Bruna I, Fuster V. Marfan syndrome.
Part  1:  pathophysiology  and  diagnosis.  Nat  Rev  Cardiol.
2010; 7:256-65. [PMID: 20351703]
22. Robinson PN, Arteaga-Solis E, Baldock C, Collod-Béroud G,
Booms P, De Paepe A, Dietz HC, Guo G, Handford PA, Judge
DP, Kielty CM, Loeys B, Milewicz DM, Ney A, Ramirez F,
Reinhardt DP, Tiedemann K, Whiteman P, Godfrey M. The
molecular genetics of Marfan syndrome and related disorders.
J Med Genet 2006; 43:769-87. [PMID: 16571647]
23. Faivre L, Collod-Beroud G, Loeys BL, Child A, Binquet C,
Gautier  E,  Callewaert  B,  Arbustini  E,  Mayer  K,  Arslan-
Kirchner M, Kiotsekoglou A, Comeglio P, Marziliano N,
Dietz HC, Halliday D, Beroud C, Bonithon-Kopp C, Claustres
M, Muti C, Plauchu H, Robinson PN, Adès LC, Biggin A,
Benetts B, Brett M, Holman KJ, De Backer J, Coucke P,
Francke U, De Paepe A, Jondeau G, Boileau C. Effect of
mutation  type  and  location  on  clinical  outcome  in  1,013
probands with Marfan syndrome or related phenotypes and
FBN1 mutations: an international study. Am J Hum Genet
2007; 81:454-66. [PMID: 17701892]
24. Faivre L, Collod-Beroud G, Child A, Callewaert B, Loeys BL,
Binquet C, Gautier E, Arbustini E, Mayer K, Arslan-Kirchner
M, Stheneur C, Kiotsekoglou A, Comeglio P, Marziliano N,
Halliday  D,  Beroud  C,  Bonithon-Kopp  C,  Claustres  M,
Plauchu H, Robinson PN, Adès L, De Backer J, Coucke P,
Francke U, De Paepe A, Boileau C, Jondeau G. Contribution
of molecular analyses in diagnosing Marfan syndrome and
type  I  fibrillinopathies:  an  international  study  of  1009
probands. J Med Genet 2008; 45:384-90. [PMID: 18310266]
25. Schrijver I, Liu W, Odom R, Brenn T, Oefner P, Furthmayr H,
Francke  U.  Premature  termination  mutations  in  FBN1:
distinct  effects  on  differential  allelic  expression  and  on
protein  and  clinical  phenotypes.  Am  J  Hum  Genet  2002;
71:223-37. [PMID: 12068374]
26. Liu WO, Oefner PJ, Qian C, Odom RS, Francke U. Denaturing
HPLC-identified  novel  FBN1  mutations,  polymorphisms,
and  sequence  variants  in  Marfan  syndrome  and  related
connective  tissue  disorders.  Genet  Test  1997-1998;
1:237-42. [PMID: 10464652]
27. Yuan  X,  Downing  AK,  Knott  V,  Handford  PA.  Solution
structure  of  the  transforming  growth  factor  beta-binding
protein-like module, domain associated with matrix fibrils.
EMBO J 1997; 16:6659-66. [PMID: 9362480]
Molecular Vision 2012; 18:81-86 <http://www.molvis.org/molvis/v18/a10> © 2012 Molecular Vision
85Appendix 1.
Appendix  1.  Primers  used  to  amplify  the  exons  of
FBN1. To access the data, click or select the words “Appendix
1.” This will initiate the download of a compressed (pdf)
archive that contains the file.
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